Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 96 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Atopic Conjunctivitis Clear all

Conditions: Chronic Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo; Drug
Lead sponsor: Fovea Pharmaceuticals SA; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: olopatadine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Allergic Rhinitis Due to Cat Allergy
Interventions: REGN1908-1909, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 42
States / cities: Mission Viejo, California • Riverside, California • Rolling Hills Estates, California + 39 more

Conditions: Allergic Conjunctivitis
Interventions: Bilastine 0.2%, Bilastine 0.4%, Bilastine 0.6%, Bilastine 0%; Drug
Lead sponsor: Faes Farma, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis (AC)
Interventions: EBI-005, Placebo Comparator; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 11
States / cities: Morrow, Georgia • Louisville, Kentucky • Andover, Massachusetts + 8 more

Conditions: Allergic Conjunctivitis
Interventions: AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%, Vehicle; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Manuka honey; Drug
Lead sponsor: Toyos Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Germantown, Tennessee • Nashville, Tennessee

Conditions: Allergic Conjunctivitis
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Andover, Massachusetts • Memphis, Tennessee

Conditions: Allergic Conjunctivitis
Interventions: TL-925, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Smyrna, Tennessee

Conditions: Allergic Conjunctivitis
Interventions: Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 10 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Irvine, California

Conditions: Allergic Conjunctivitis
Interventions: bepotastine besilate, 1.5%, Loteprednol etabonate; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Fullerton, California

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Rhinitis, Asthma, Allergic Conjunctivitis
Interventions: Allergen(Tree, Grass, Weeds); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: South Euclid, Ohio

Conditions: Allergic Rhinoconjunctivitis
Interventions: Not listed
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Keratoconus, Dry Eye, Allergy
Interventions: dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly; Drug
Lead sponsor: Illinois College of Optometry; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Disease (Including Allergic Conjunctivitis)
Interventions: Drug: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Conjunctivitis, Allergic
Interventions: alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 10 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Allergic Conjunctivitis
Interventions: alacaftadine and naphazoline HCl & pheniramine maleate; Drug
Lead sponsor: Hom, Milton M., OD, FAAO; Individual
Eligibility: 18 Months and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Azusa, California

Conditions: Allergic Conjunctivitis
Interventions: SPARC1102 I, SPARC1102 II, SPARC1102 III, Vehicle; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 10 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Conjunctivitis, Allergic
Interventions: Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 10 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Allergic Conjunctivitis
Interventions: Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID), Loteprednol etabonate suspension, Vehicle of loteprednol etabonate; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 10 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

Effect of Olopatadine on Allergic Tear Mediators

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis

Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model

Manuka Eye Droops for Treatment of Allergy

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis

Comparison of Tolerability Between Two Allergy Drops

Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge